
Prime Medicine, Inc.
93
Recent developments include positive clinical data announcements, strategic restructuring, significant funding from the Cystic Fibrosis Foundation, insider share purchases, and multiple stock price increases reported in the news.
- Prime Medicine secured up to $24 million from the Cystic Fibrosis Foundation to advance prime editing technology for cystic fibrosis treatment [N2].
- The company announced positive Phase 1/2 clinical data for PM359 and strategic restructuring focused on liver disease programs [N8].
- An insider owning 10% of the company purchased 21,000 shares [N6].
- Multiple news reports noted significant daily stock price increases ranging from 7% to 20% on various dates in mid-2025 [N1][N3][N4][N5][N7].
Prime Medicine, Inc. operates in the biotechnology sector, developing therapies using prime editing technology aimed at treating genetic diseases. The company is in clinical stages with no commercial products or revenue. It has focused research and development efforts on liver disease programs and chronic granulomatous disease, with ongoing clinical trials and preclinical programs such as for Alpha-1 Antitrypsin Deficiency. The company has raised capital through public offerings and collaborations, including a recent $24 million funding from the Cystic Fibrosis Foundation. Financial disclosures indicate significant operating losses and a need for continued financing to support development activities.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Prime Medicine, Inc. is a clinical-stage biotech company focused on prime editing technology for genetic diseases. The company has reported significant operating losses and no product revenue to date. Recent SEC filings disclose detailed operating expenses, clinical progress including positive Phase 1/2 data for PM359, and strategic restructuring focused on liver disease programs. The company secured up to $24 million from the Cystic Fibrosis Foundation to advance cystic fibrosis treatment. As of September 30, 2026, the company held $54.9 million in cash and equivalents with a current ratio of 1.79. Substantial doubt about going concern exists based on 2025 filings, contingent on raising additional capital. The company plans to finance operations through equity offerings and collaborations.
Prime Medicine's positive Phase 1/2 clinical data for PM359 and strategic focus on liver disease programs demonstrate progress in advancing its pipeline. Securing substantial funding from the Cystic Fibrosis Foundation highlights external validation of its technology. The company's proprietary prime editing platform offers potential for precise genetic therapies addressing unmet medical needs. Continued capital raises and collaborations could support sustained development and eventual commercialization efforts.
Prime Medicine has incurred significant operating losses with no product revenue and substantial doubt about its ability to continue as a going concern without additional financing. The company faces risks typical of clinical-stage biotechs, including clinical trial failures, regulatory hurdles, and the need for ongoing capital. Workforce reductions and restructuring indicate operational challenges. Dependence on equity offerings and collaborations for funding may dilute shareholder value and impact strategic flexibility.
Prime Medicine's moat is based on its proprietary prime editing technology platform, which aims to enable precise genetic modifications for treating a range of genetic diseases. The company's focus on in vivo liver disease programs and strategic collaborations, including funding from disease foundations, supports its competitive positioning. However, as a clinical-stage biotech without commercial products, its moat depends on successful clinical development, regulatory approvals, and intellectual property protection.
• Financing Risk: The company has substantial doubt about its ability to continue as a going concern within one year from the 2025 10-K filing date, dependent on obtaining additional financing through equity offerings or collaborations.
• Clinical and Regulatory Risk: Prime Medicine's therapies are in early clinical and preclinical stages, facing risks of trial failures, regulatory delays, or inability to obtain approvals.
• Operational Risk: Workforce reductions and strategic restructuring may impact operational execution and program prioritization.
• Market and Competitive Risk: The biotechnology sector is highly competitive with rapid technological changes and competing gene editing platforms.
Business trends: Advancement of prime editing technology with clinical progress in PM359 and strategic focus on liver disease programs; securing funding from disease foundations.
Execution milestones: Positive Phase 1/2 clinical data announcements; public equity offerings raising significant capital; strategic restructuring to prioritize programs.
Key risks: Substantial doubt about going concern without additional financing; clinical and regulatory uncertainties; operational challenges from restructuring and workforce changes.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Prime Medicine, Inc. is a clinical-stage biotechnology company focused on developing therapies using prime editing technology.
- The company has incurred significant operating losses since inception and has not yet commercialized any products, with no revenue from product sales reported.
- Research and development expenses increased by $5.3 million in 2025 compared to 2024, driven by facility expansion, license and IP costs, professional fees, and clinical expenses related to Wilson Disease and Alpha-1 Antitrypsin Deficiency (AATD) programs.
- Personnel expenses decreased due to workforce reduction in May 2025.
- General and administrative expenses increased slightly due to higher professional and consultant fees, mainly corporate legal expenses.
- Prime Medicine secured up to $24 million from the Cystic Fibrosis Foundation to advance prime editing technology for cystic fibrosis treatment.
- Positive Phase 1/2 clinical data was announced for PM359, a candidate for chronic granulomatous disease, alongside strategic restructuring focused on liver disease programs.
- The company completed a public offering in August 2025, raising approximately $138.4 million net proceeds.
- As of September 30, 2026, Prime Medicine had $54.9 million in cash and cash equivalents, current assets of $63.7 million, current liabilities of $35.6 million, a current ratio of 1.79, and a cash ratio of 1.54.
- Net loss for the quarter ended September 30, 2026 was $39.0 million with basic and diluted EPS of -$0.22.
- The company maintains a shelf registration statement for issuing securities and an at-the-market offering program with Jefferies LLC.
- Substantial doubt exists about the company's ability to continue as a going concern within one year from the 2025 10-K filing date, dependent on obtaining additional financing.
- The company plans to fund operations through equity offerings, collaborations, and strategic partnerships.
- Recent insider purchase activity includes a 10% owner buying 21,000 shares.
- The company announced a preclinical program for Alpha-1 Antitrypsin Deficiency using prime editing technology.
Generated 2026-11-15
- S1 | 2026-03-03 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2025-07-21 | www.nasdaq.com | $PRME stock is up 16% today. Here's what we see in our data. | https://www.nasdaq.com/articles/prme-stock-16-today-heres-what-we-see-our-data
- N2 | 2025-07-16 | www.nasdaq.com | Prime Medicine Secures Up to $24 Million from Cystic Fibrosis Foundation to Advance Prime Editing Technology for Cystic Fibrosis Treatment | https://www.nasdaq.com/articles/prime-medicine-secures-24-million-cystic-fibrosis-foundation-advance-prime-editing
- N3 | 2025-07-09 | www.nasdaq.com | $PRME stock is up 12% today. Here's what we see in our data. | https://www.nasdaq.com/articles/prme-stock-12-today-heres-what-we-see-our-data
- N4 | 2025-07-02 | www.nasdaq.com | $PRME stock is up 20% today. Here's what we see in our data. | https://www.nasdaq.com/articles/prme-stock-20-today-heres-what-we-see-our-data
- N5 | 2025-06-17 | www.nasdaq.com | $PRME stock is up 13% today. Here's what we see in our data. | https://www.nasdaq.com/articles/prme-stock-13-today-heres-what-we-see-our-data
- N6 | 2025-06-12 | www.nasdaq.com | Insider Purchase: 10% owner at $PRME Buys 21,000 Shares | https://www.nasdaq.com/articles/insider-purchase-10-owner-prme-buys-21000-shares
- N7 | 2025-06-05 | www.nasdaq.com | $PRME stock is up 7% today. Here's what we see in our data. | https://www.nasdaq.com/articles/prme-stock-7-today-heres-what-we-see-our-data
- N8 | 2025-05-19 | www.nasdaq.com | Prime Medicine, Inc. Announces Positive Phase 1/2 Data for PM359 and Strategic Restructuring Focused on Liver Disease Programs | https://www.nasdaq.com/articles/prime-medicine-inc-announces-positive-phase-1-2-data-pm359-and-strategic-restructuring
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


